FASN and urinary bladder cancer: A recent study identified that simvastatin (HMGCR inhibitor) use can reduce bladder cancer risk, and the FASN inhibitor TVB-2640 is currently being examined in different phase II clinical trials, although it is not currently approved as an independent cancer treatment [78,79,80].